Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “BREAST DISEASES”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 55 records · Page 3Linked to original sources
PubMed1992

[Growth factors of cultured epithelial cells of breast diseases and breast carcinoma].

Primary cultures of non-malignant human breast tissues, benign mastopathies and breast carcinomas were raised in defined culture conditions and characterized for in vitro cell proliferation. Although some mastopathies had estradiol receptors they did not respond to hormone treatment. Epidermal growth factor (EGF) was capable of stimulating the 3 types of primary culture. In contrast, dexamethasone, insulin and transferrin stimulated only the proliferation of some benign mastopathies and carcinoma cells. Cholera toxin increased the cell growth of normal tissues and mastopathies but not of carcinoma in primary cultures. Taken together, these results show that epithelial cells from mastopathies differ from one another; some are similar to non-malignant cells, whereas others are comparable to tumor cells.

Breast Diseases↗
PubMedDate not supplied

ASPO Distinguished Achievement Award Lecture. Studies on the epidemiology and natural history of benign breast disease and breast cancer using nipple aspirate fluid.

Nicholas L. Petrakis, M.D., was presented the American Society of Preventive Oncology's Distinguished Achievement Award at the Society's annual meeting on March 15, 1992, in Bethesda, Maryland. The basis for choosing Dr. Petrakis was his distinguished achievements for over 20 years in research and education concerning the etiology and prevention of cancer, with substantial emphasis on breast cancer. Dr. Petrakis obtained a Bachelor of Arts degree from Augustana College, Sioux Falls, South Dakota, and his Doctor of Medicine degree from Washington University, St. Louis, Missouri. He has held numerous principal positions at the University of California, beginning with a position with the U.S. Public Health Service, National Cancer Institute Laboratory of Experimental Oncology, and then the Cancer Research Institute, both at the University of California, San Francisco. Dr. Petrakis has held continuing appointments in the Department of Preventive Medicine and Department of Epidemiology and International Health, beginning as an Assistant Professor. He was subsequently promoted to Associate Professor and Professor of Preventive Medicine. During the years from 1978 to 1989, Dr. Petrakis was chair of the Department of Epidemiology and International Health. Since 1981 he has been Professor of Epidemiology, University of California, Berkeley, School of Public Health. In 1989 he became Professor Emeritus of Preventive Medicine and Epidemiology.(ABSTRACT TRUNCATED AT 250 WORDS)

Adult↗
PubMed1998

[Telomerase activity in benign proliferative breast disease and breast cancer].

The application of telomerase activity is expected to serve as a reliable indicator of biological malignancy in breast tumors. We performed a study to quantify telomerase activity, the results of which revealed that this activity tends to be unexpectedly low in scirrhous carcinoma having low histological differentiation. It is therefore felt that additional studies at the tissue level using in situ hybridization will be required in the future. Although we think that atypical cystic duct is a true pre-cancerous lesion in the sense of having a high possibility of progressing into breast cancer, it will be interesting to determine whether or not the tissue is composed of cells having telomerase activity.

Breast Diseases↗
PubMed1983

Retrospective assessment of menstrual cycle length in patients with breast cancer, in patients with benign breast disease, and in women without breast disease.

The length of the menstrual cycle was compared in women with breast cancer, women with benign breast disease, and controls. Older women in general tended to report shorter menstrual cycles (P less than 0.05). After correction for the age difference, breast cancer patients still reported a shorter average menstrual cycle length than benign breast disease patients and controls (P less than 0.006). Very short cycles (less than or equal to 21 days) were present in 20% of the breast cancer patients compared to 8% of the patients with benign breast disease and 4% of the controls (P less than 0.0001). Long cycles (less than or equal to 30 days) were not a feature of breast cancer patients (2%), whereas 20% of the patients with benign breast disease and 20% of the controls reported such long cycles (P less than 0.0001). Irregular menstrual cycles were more common in benign breast disease patients (20%) than in cancer patients (10%) and controls (8%) (P less than 0.001).

Adult↗
PubMed1990

[Mammaplasty. A component of the combined therapy program in the treatment of malignant breast diseases].

Breast reconstruction following mastectomy is a part of programme in rehabilitation. The type of reconstruction is determined by the local defect. 1. The advanced skin technique with or without skin expander and silicone breast implant is in this time the most used procedure. 2. If needed skin the thoracoepigastric flap is used. 3. If additional skin and muscular cover is needed, the latissimus dorsi flap, lower m. rectus abdominis flap, the upper m. rectus abdominis flap are used or free flap.

Breast↗
PubMed1994

GnRH analogs in benign breast disease and breast cancer chemoprevention. A challenge for the year 2000.

GNRH analogs (GNRHAs) are currently used in the treatment of prostatic and breast cancer and in several benign gynecological conditions. Because of their ability to suppress sex hormone secretion and the supposed role of these hormones in the physiopathology of fibrocystic mastopathy, GNRHAs have been proposed for the management of severe breast pain and nodularity. In preliminary studies the treatment with GNRHAs for 3-6 months improves clinical and radiologic manifestations of mastopathy, also when breast pain has been recurrent or refractory to other hormonal drugs. Further studies are required to determine the optimal length of treatment and the adverse effects induced by estrogen deficiency in premenopausal women. There is evidence that an early menopause reduces woman's lifetime risk of breast cancer. According to this data, a high-dose GNRHAs regimen associated with estrogen replacement therapy (ERT) has been proposed as chemopreventive agent for premenopausal women at high risk of breast cancer. The definition of the long term effects of GNRHAs on bone and lipid metabolism is essential before a large trial of chemoprevention can be carried out.

Breast Neoplasms↗
PubMed1985

Evaluation of luteal-phase salivary progesterone levels in women with benign breast disease or primary breast cancer.

Salivary progesterone concentrations were determined in premenopausal parous women with a mean age of ca. 40 yr who had a history of either benign breast disease (n = 15) or primary breast cancer (n = 15) and in a group of age-matched healthy women (n = 15). Saliva samples were collected at 09.00 and 21.00 hr daily for one complete menstrual cycle and progesterone concentration was measured by radioimmunoassay. Characteristic luteal-phase progesterone profiles were observed in all subjects in each of the three groups but no statistical intergroup differences could be demonstrated for age-matched subjects in each group. These studies indicated that ovarian dysfunction, as judged from salivary progesterone concentrations, was not apparent in older premenopausal women with a history of benign breast disease or primary breast cancer when compared with age-matched controls.

Adult↗
PubMed1996

Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue.

Prostate specific antigen (PSA) is a tumor marker used widely for the diagnosis and monitoring of prostatic adenocarcinoma. Recently, we provided evidence that PSA may also be produced by breast tumors. In this report we examined quantitatively the PSA levels in 199 breast tumors, 48 tissues with benign breast disease (BBD, 34 fibroadenomas), and 36 normal breast tissues. Significant amounts of PSA (> or = 0.030 ng of PSA per mg of total protein) were found in 28% of breast tumors, 65% of BBD tissues, and 33% of normal breast tissues. PSA positivity in breast tumors was highest in stage I disease (34%) and decreased with disease stage (24% in stage II and 18% in stage III-IV). Using polymerase chain reaction amplification we have shown PSA mRNA presence in patients with PSA protein-positive tissues (benign and malignant) but not in patients with PSA protein-negative tissues. Our data suggest that PSA is expressed frequently by normal breast tissue, by tissue of benign breast diseases, and by breast cancer tissue. Highest expression is seen in benign breast disease and lowest expression in advanced stage cancerous tissue. As PSA production is mediated by steroid hormones and their receptors, we propose that PSA may be a new marker of steroid hormone action in the normal or diseased female breast. The role of this enzyme in the development of breast diseases including breast cancer is currently unknown.

Adolescent↗